Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine the bioavailability (the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action) of two tablet formulations of Neratinib (HKI-272) compared to the capsule formulation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | 40-mg tablet |
|
| 2 | Experimental | 240-mg tablet |
|
| 3 | Experimental | 80-mg capsule |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| neratinib | Drug | HKI-272 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Blood will be collected to determine the pharmacokinetics of the various formulations of HKI-272 | 6 weeks |
Not provided
Not provided
Healthy male and female subjects, ages 18-50.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Puma | Biotechnology | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tacoma | Washington | 98418 | United States |
Not provided
| ID | Term |
|---|---|
| C487932 | neratinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided